1496-40-8

Usage

Uses

Used in Pharmaceutical Research:
N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PIPERIDINE is used as a research compound for its potential in developing new drugs due to its ability to interact with biological receptors and enzymes, which is crucial for the creation of therapeutic agents.
Used in Drug Design:
In the pharmaceutical industry, N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PIPERIDINE is used as a molecular scaffold to facilitate the design of drugs, leveraging the trifluoromethylphenyl group's affinity for biological targets and the amino group's capacity for further molecular interactions.
Used in Chemical Research:
N-(2-AMINO-4-TRIFLUOROMETHYLPHENYL)PIPERIDINE is utilized in chemical research laboratories for studying its properties and reactions, contributing to the broader understanding of chemical compounds with similar structures and their potential applications.

InChI:InChI=1/C12H15F3N2/c13-12(14,15)9-4-5-11(10(16)8-9)17-6-2-1-3-7-17/h4-5,8H,1-3,6-7,16H2

Upstream product

• 1692-79-1 1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine 
• 98-16-8 3-trifluoromethylaniline 
• 61350-01-4 N-[3-(trifluoromethyl)phenyl]-2-pyridinecarboxamide 
• 110-89-4 piperidine 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 

Downstream Products

• 926036-43-3 2-fluoro-5-iodo-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide 
• 688033-18-3 3-iodo-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide 
• 926036-42-2 3-iodo-4-methyl-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzamide 
• 218156-96-8 SRPIN340 
• 781636-08-6 7-methyl-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide 

Relevant academic research and scientific papers

Electroreductive heterocyclization of ortho-piperidino substituted nitro(het)arenes

Electrochemical reduction of ortho-piperidino substituted nitro(het)arenes in an undivided cell on a lead cathode in 8% HCl gave either 1,2,3,4-tetrahydropyrido[1,2-a]-benzimidazoles or 6,7,8,9-tetrahydropyrido[3′,2′:4,5]- imidazo[1,2-a]pyridines. The red

Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity

Malaria is a devastating parasitic disease caused by parasites from the genus Plasmodium. Therapeutic resistance has been reported against all clinically available antimalarials, threatening our ability to control the disease and therefore there is an ongoing need for the development of novel antimalarials. Towards this goal, we identified the 2-(N-phenyl carboxamide) triazolopyrimidine class from a high throughput screen of the Janssen Jumpstarter library against the asexual stages of the P. falciparum parasite. Here we describe the structure activity relationship of the identified class and the optimisation of asexual stage activity while maintaining selectivity against the human HepG2 cell line. The most potent analogues from this study were shown to exhibit equipotent activity against P. falciparum multidrug resistant strains and P. knowlesi asexual parasites. Asexual stage phenotyping studies determined the triazolopyrimidine class arrests parasites at the trophozoite stage, but it is likely these parasites are still metabolically active until the second asexual cycle, and thus have a moderate to slow onset of action. Non-NADPH dependent degradation of the central carboxamide and low aqueous solubility was observed in in vitro ADME profiling. A significant challenge remains to correct these liabilities for further advancement of the 2-(N-phenyl carboxamide) triazolopyrimidine scaffold as a potential moderate to slow acting partner in a curative or prophylactic antimalarial treatment.

Copper-catalyzed: Ortho -C(sp2)-H amination of benzamides and picolinamides with alkylamines using oxygen as a green oxidant

A versatile Cu-catalyzed direct ortho-C(sp2)-H amination of benzamides and picolinamides with alkylamines has been achieved. This method employs cheap and eco-friendly copper as a catalyst and oxygen as an oxidant, and also has the advantages of straightf

Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1

ERAP1 is an endoplasmic reticulum-resident zinc aminopeptidase that plays an important role in the immune system by trimming peptides for loading onto major histocompatibility complex proteins. Here, we report discovery of the first inhibitors selective for ERAP1 over its paralogues ERAP2 and IRAP. Compound 1 (N-(N-(2-(1H-indol-3-yl)ethyl)carbamimidoyl)-2,5-difluorobenzenesulfonamide) and compound 2 (1-(1-(4-acetylpiperazine-1-carbonyl)cyclohexyl)-3-(p-tolyl)urea) are competitive inhibitors of ERAP1 aminopeptidase activity. Compound 3 (4-methoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid) allosterically activates ERAP1's hydrolysis of fluorogenic and chromogenic amino acid substrates but competitively inhibits its activity toward a nonamer peptide representative of physiological substrates. Compounds 2 and 3 inhibit antigen presentation in a cellular assay. Compound 3 displays higher potency for an ERAP1 variant associated with increased risk of autoimmune disease. These inhibitors provide mechanistic insights into the determinants of specificity for ERAP1, ERAP2, and IRAP and offer a new therapeutic approach of specifically inhibiting ERAP1 activity in vivo.

Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs)

The serine/arginine-rich protein kinases (SRPKs) have frequently been found with altered activity in a number of cancers, suggesting they could serve as potential therapeutic targets in oncology. Here we describe the synthesis of a series of twenty-two tr

ANILINE DERIVATIVE HAVING ANTI-RNA VIRAL ACTIVITY

Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase

The recognition that aberrant angiogenesis contributes to the pathology of inflammatory diseases, cancer, and myocardial ischemia has generated considerable interest in the molecular mechanisms that regulate blood vessel growth. The receptor tyrosine kinase Tie-2 is expressed primarily by vascular endothelial cells and is critical for embryonic vasculogenesis. Interference with the Tie-2 pathway by diverse blocking agents such as soluble Tie-2 receptors, anti-Tie-2 intrabodies, anti-Ang-2 antibodies, and peptide-F c conjugates has been shown to suppress tumor growth in xenograft studies. An alternative strategy for interfering with the Tie-2 signaling pathway involves direct inhibition of the kinase functions of the Tie-2 receptor. Herein we describe the development of alkynylpyrimidine amide derivatives as potent, selective, and orally available ATP-competitive inhibitors of Tie-2 autophosphorylation.

METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT

The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhi

Methine dyes

The invention relates to a new class of pyrrolobenzimidazole, benzimidazoloisoquinoline and dipyrodinobenzodiimidazole in cyanine sensitizing dyes derived therefrom and their use in silver halide emulsions, and to methods for preparation of such new dyes.